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Eighty percent of malignant tumors that develop in the central nervous system are malignant
gliomas, which are essentially incurable. Here, we discuss how recent sequencing studies are iden-
tifying unexpected drivers of gliomagenesis, includingmutations in isocitrate dehydrogenase 1 and
the NF-kB pathway, and how genome-wide analyses are reshaping the classification schemes for
tumors and enhancing prognostic value of molecular markers. We discuss the controversies
surrounding glioma stem cells and explore how the integration of new molecular data allows for
the generation of more informative animal models to advance our knowledge of glioma’s origin,
progression, and treatment.Although the total incidence of primary central nervous system
(CNS) tumors is only about 18.7 per 100,000 persons in the
United States, 80% of the malignant tumors in the CNS are
malignant gliomas, which are essentially incurable (CBTRUS,
2009). Gliomas display histological similarities to glial cells,
including astrocytes and oligodendrocytes. According to the
2007 World Health Organization (WHO) classification, malignant
gliomas can be classified according to which cell they most
resemble, such as astrocytomas, oligodendrogliomas, or oli-
goastrocytomas. More than half of gliomas are glioblastoma
multiforme (GBM, grade IV astrocytoma), one of the most
aggressive cancers (Louis et al., 2007). Despite decades of
concerted effort and advances in surgery, radiation, and chemo-
therapy, the overall 5 year survival rate of GBM remains less than
5% and is even worse for elderly patients (CBTRUS, 2009). This
dismal clinical outcome makes glioma an urgent subject of
cancer research. Here, we discuss current advances in genomic
analysis and genetic modeling of glioma and how these develop-
ments influence strategies for therapeutic intervention in this
deadly disease.
Genetics of Glioma
Glioma Core Signaling Pathways
In the past two decades, cytogenetic and molecular genetic
studies have identified a number of recurrent chromosomal
abnormalities and genetic alterations in malignant gliomas,
particularly in GBM. Advances in molecular technologies, espe-
cially high-density microarray and genome sequencing, have
made it possible to evaluate genetic and epigenetic changes in
these tumors at the genome-wide level. In a comprehensive
study carried out by The Cancer Genome Atlas (TCGA) project,
601 cancer-related candidate genes were sequenced in more
than 200 human GBM samples (TCGA, 2008). The project also
analyzed genome-wide DNA copy number changes, DNA meth-
ylation status, and protein-coding and noncoding RNA expres-
sion (TCGA, 2008). A similar but complementary study by36 Cell 149, March 30, 2012 ª2012 Elsevier Inc.Parsons et al. sequenced 20,661 protein-encoding genes in 22
GBM samples and integrated the genetic alteration information
with DNA copy number and gene expression profiles (Parsons
et al., 2008).
These integrative genomic studies provided a comprehensive
view of the complicated genomic landscape of GBM, revealing
a set of core signaling pathways commonly activated in GBM
(Figure 1): the P53 pathway, the RB pathway, and the RTK
pathway (TCGA, 2008; Parsons et al., 2008). Furnari et al. have
written a detailed review of these pathways in glioma (Furnari
et al., 2007). The majority of GBM tumors have genetic alter-
ations in all three pathways, which helps to fuel cell proliferation
and enhance cell survival while allowing the tumor cell to escape
from cell-cycle checkpoints, senescence, and apoptosis. In
addition to confirming known genetic events, the TCGA
sequencing data also provided somatic mutation information at
the base pair level, revealing potential new roles for known tumor
suppressors/oncogenes in GBM as well as new cancer driver
genes. For example, it has long been observed that patients
with germline mutations in the tumor suppressor gene respon-
sible for neurofibromatosis type 1 (NF1) have an increased
incidence of malignant glioma (Gutmann et al., 2002; Friedman,
1999). Studies in genetic mouse models have also strongly sug-
gested a causal role for NF1 mutation in glioma tumorigenesis
(Alcantara Llaguno et al., 2009; Kwon et al., 2008; Zhu et al.,
2005). However, the involvement of NF1 mutation in sporadic
human GBM remained underappreciated until the TCGA project
reported that 47 of the 206 patient samples, or 23%, had NF1
mutations or deletions, ranking it as the third most frequently
somatically mutated gene among the 601 genes sequenced
(TCGA, 2008).
In addition to the core signaling pathways identified through
genome-wide screening studies, Harsh et al. recently reported
that heterozygous deletion of the NF-kB inhibitor a (NFKBIA)
gene was present in a quarter of GBM samples (Bredel et al.,
2011). The NFKBIA gene encodes the protein IkBa, a crucial
Figure 1. Core Signaling Pathways in
Glioma Tumorigenesis
The receptor tyrosine kinase (RTK), p53, and Rb
pathways are the core signaling pathways in
glioma oncogenesis. Red indicates oncogenes
that are either overexpressed or amplified in GBM
samples, and blue indicates tumor suppressor
genes that are somatically mutated or deleted
(except for P27 and P21).negative regulator in the canonical NF-kB signaling pathway.
Under basal conditions, IkBa sequesters the NF-kB transcription
factor heterodimer (p50/p65) in the cytoplasm. Upon stimulation
with ligand such as tumor necrosis factor a (TNF-a) or lipopoly-
saccharide (LPS), IkBa is phosphorylated by the signalosome
(Karin, 2006). This phosphorylation leads to rapid ubiquitination
and degradation of IkBa, which releases the inhibition of
NF-kB and allows translocation of p50/p65 into the nucleus to
activate transcription of downstream target genes, including
many cytokines that can promote tumor growth and infiltration
(Karin, 2006).
In GBM, NFKBIA deletion and EGFR amplification aremutually
exclusive, raising the possibility that the two genetic events
converge on the same pathway. Indeed, overexpression of
NFKBIA reduced the viability of primary glioma cells in which
NFKBIA was downregulated or EGFR was upregulated (Bredel
et al., 2011). In addition, both genetic events were associated
with similar prognostic outcome, which is inferior to that of
patients with normal expression levels of these two genes.
However, the detailed molecular mechanism for the role of
NF-kB in glioma development and progression and its connec-
tion with EGFR signaling remain to be investigated.
IDH Mutations in Glioma
Among the various genomic efforts to characterize gliomas, the
biggest surprise came from the genome-wide exon sequencing
project, in which R132 mutations of isocitrate dehydrogenase 1
(IDH1) were observed in 12% of the GBM samples (Parsons
et al., 2008). Subsequent studies revealed that as many as
70%–90%of the grade II/III gliomas harbored this IDH1mutation
(Yan et al., 2009). Other studies have demonstrated that some
gliomas contain IDH2 R172 mutations, an analog to IDH1
R132, at a lower frequency (Yan et al., 2009). Two additionalCell 1point mutations, IDH1 R100 and IDH2
R140, have been reported in AML but
have not been observed in human glioma
samples (Green and Beer, 2010).
Normally, IDH1 and IDH2 convert isoci-
trate to a-ketoglutarate (a-KG) while at
the same time reducing NADP+ to
NADPH in the cytosol and mitochondria,
respectively (Figure 2) (Reitman et al.,
2010). It was initially hypothesized that
the IDH1 R132 and IDH2 R172 mutations
reduced the enzyme’s ability to generate
a-KG (Yan et al., 2009). Subsequent
studies reported a dominant-negative
role for IDH1R132 and suggested a tumor
suppressor function for IDH1/2 (Zhaoet al., 2009). However, human genetic data showed that the
mutations were always observed on a specific residue and
only in one allele of the gene. These apparently narrow con-
straints on the nature of the mutations raised the possibility of
neomorphic (gain-of-function) mutations (Green and Beer,
2010; Reitman et al., 2010; Yan et al., 2009). Follow-up studies
discovered that the IDH1/2 mutations had an NADPH-depen-
dent ability to convert a-KG to D-2-hydroxyglutarate (D-2HG)
(Figure 2), supporting a pro-oncogenic role for IDH1/2 (Dang
et al., 2010; Ward et al., 2010). Consistent with this model,
knocking down wild-type IDH1 in a glioma cell line slowed cell
growth, and levels of 2HG were found to be 10-fold higher in
IDH1/2 mutated glioma or leukemia samples (Dang et al.,
2010; Ward et al., 2010).
Despite this intriguing data, the mechanism by which IDH1/2
mutations transform cells is far from clear. The discovery of a
neomorphic enzymatic function for IDH1/2 raises the possibility
that D-2HG may act as an oncometabolite (Dang et al., 2010;
Ward et al., 2010). It has been reported that increased levels of
D-2HG in cells caused oxidative stress in rat brains (Latini
et al., 2003), which could potentially promote oncogenesis. In
the clinic, high levels of 2HG have been linked to a rare neurome-
tabolic disorder called D-2-hydroxyglutaric aciduria (Kranendijk
et al., 2010). A subset of patients with this disease was found
to harbor IDH2 R140 mutations. Though the patients showed
significantly higher levels of D-2HG compared to leukemia or
glioma patients with IDH1/2 mutations, they did not develop
gliomas, leukemia, or other malignancies (Kranendijk et al.,
2010). In glioma patients, IDH1/2 mutations usually coexist
with TP53 mutations (Yan et al., 2009). It is possible that, like
other oncogenic stresses that trigger cell death and senescence,
cells with extremely high levels of 2HG may be restrained49, March 30, 2012 ª2012 Elsevier Inc. 37
Figure 2. Function of Normal and Mutated
IDH1
Wild-type IDH1 catalyzes isocitrate to form a-ke-
toglutarate and convert NADP+ to NADPH at the
same time. A mutated form of IDH1 can convert
a-ketoglutarate to D2-hydroxyglutarate in an
NADPH-dependent manner. Excessive D2-hy-
droxyglutarate results in cellular stress as well as
metabolic changes. It could also potentially act
as a competitive substrate to inhibit DNA/histone
methyltransferases and prolyl hydroxylases
(PHDs), resulting in DNA/histone hypomethylation
or activation of HIF-1a, which can be further
accelerated by the lack of a-ketoglutarate, as
a-ketoglutarate is a key substrate for both PHDs
and DNA/histone methyltransferases.from further malignant transformation by a similar checkpoint
mechanism.
In addition, other substrates/products affected by the IDH1/2
mutations may also contribute to oncogenesis. Disrupting the
balance of NADP+/NADPH is likely to result in a broad spectrum
of cellular reactions, and a-KG is a key component of multiple
pathways. For example, a-KG is a key substrate for prolyl
hydroxylase domain proteins (PHDs) to catalyze hydroxylation
of hypoxia-inducible factor (HIF), a key regulator of angiogenesis
(Figure 2) (Semenza, 2010). This hydroxylation allows HIF to be
recognized and targeted for ubiquitin-mediated protein degra-
dation. It has been observed that overexpression of IDH1 R132
in glioma cell lines resulted in increased levels of HIF-1a (Zhao
et al., 2009). However, whether cells with IDH1/2 mutations
have lower levels of a-KG is still controversial (Dang et al.,
2010; Zhao et al., 2009). Given the structural similarity of a-KG
and D-2HG, it is also possible that the new product D-2HG
can compete with a-KG. Such competition has been linked to
the oncogenic mechanism of succinate dehydrogenase (SDH)
and fumarate hydratase (FH) mutations, in which accumulated
succinate and fumarate compete with a-KG to inhibit the activity
of PHDs (Semenza, 2010). In addition, a-KG is a substrate for
particular histone and DNA demethylation enzymes (Figure 2).
Reducing a-KG levels or levels of competing substrate would
likely affect global gene expression. Indeed, 2-HG can inhibit
multiple a-KG-dependent dioxygenases, which are important
for DNA/histone demethylation (Xu et al., 2011). Consistent
with this idea, gliomas with IDH1 mutations showed significantly
higher frequency of the CpG island methylator (CIM) phenotype
and increased histone demethylation (Noushmehr et al., 2010).
Molecular Subclassification of Gliomas
Subclassification of GBM by congruence of genomic features
has taken precedence in the field. A detailed summary of the38 Cell 149, March 30, 2012 ª2012 Elsevier Inc.recent progress and problems related to
this topic can be found in a recent review
by Vitucci et al. (Vitucci et al., 2011). In
general, genome-wide studies have re-
vealed that tumor histology correlates
with distinct gene expression signatures.
Furthermore, molecular profiles can iden-
tify subclasses of tumors that would
otherwise be indistinguishable by stan-dard morphological methods. One such example is primary
and secondary GBM. Although the histology of both types of
GBM is identical, primary GBM is thought to arise de novo,
and secondary GBM has a longer history of disease progression
from lower-grade tumors (Ohgaki and Kleihues, 2007). Recently,
however, several groups have used genome-wide analyses to
successfully categorize these two subtypes based on their
gene expression profiles (Maher et al., 2006; Tso et al., 2006).
Depending on the sample pool and analysismethods, different
studies have reported different numbers of subclasses. For
example, Li et al. published their molecular analysis of glioma
using two different unsupervised methods; they reported two
main types, oligodendroglioma-rich (O) and glioblastoma-rich
(G), which could be further divided into six subtypes (Li et al.,
2009a). Verhaak et al. performed unsupervised clustering anal-
ysis of the TCGA GBM data set and grouped the tumors into
four subtypes termed proneural (PN), neural (NL), mesenchymal
(MES), and classical (CL) (Verhaak et al., 2010). The PN andMES
subtypes shared significant overlap with previous studies. Inte-
gration of genetic alteration events revealed that PN, MES, and
CL subtypes were associated with aberrant PDGFRA/IDH1,
NF1, and EGFR status, respectively. Gravendeel et al. also
used an unsupervised algorithm to classify profiles of 276
gliomas into 24 different molecular ‘‘clusters,’’ or subtypes
(Gravendeel et al., 2009). A similar proneural subtype (C17)
was also identified. A large number of these classification studies
have now been carried out and provide interesting insights into
the molecular nature of these tumors, as well additional ques-
tions and problems to pursue (Vitucci et al., 2011).
The prognostic value of the molecular subclassification has
also been evaluated, with several studies suggesting that
gliomas with expression of genes associated with neurogenesis
(proneural subtype) generally correlate with marginally improved
survival (Vitucci et al., 2011). In contrast, gliomas with mesen-
chymal gene expression (mesenchymal subtype) usually have
a poorer outcome (1 year for proneural versus 0.6 years for
mesenchymal) (Vitucci et al., 2011). In an early study by Phillips
et al., the proneural subtype included a significant proportion
of grade III gliomas, which have a more favorable outcome
compared to the more aggressive GBM (Phillips et al., 2006).
Thus, it is possible that the difference in patient survival merely
reflects the known survival differences associated with tumor
grade. This problem was emphasized by the TCGA study in
which only GBM samples were analyzed. No prognostic differ-
ences were observed among the four different subtypes re-
vealed in the TCGA study (Verhaak et al., 2010). However, the
C17 (PN) subtype in the Gravendeel study was found to have
prolonged survival in either all of the gliomas or in the pure
GBM population, confirming that the previous prognostic value
of the molecular markers was not just the consequence of the
selection methods, where markers were chosen based on their
association with outcome in the training data sets (Gravendeel
et al., 2009).
Although gliomas with proliferative or mesenchymal charac-
teristics generally have a worse outcome, several studies have
confirmed that these subtypes are also more sensitive to combi-
national radiation and chemotherapy, which could reflect the
higher proliferative index or higher levels of microvascular endo-
thelial proliferation (Gravendeel et al., 2009; Verhaak et al., 2010).
Clinical trials designed based on this molecular subtype informa-
tion are ongoing. At the same time, molecular mechanisms
underlying the mesenchymal transformation of glioma have
been studied by sophisticated in silico network analysis based
on gene expression data and subtype classification. These
data point to overexpression of transcription factor C/EBPb
and activation of STAT3 as driving forces of mesenchymal trans-
formation (Carro et al., 2010).
Lessons from Genomic Studies
The wealth of genomic data that is now available for glioma
provides tremendous opportunity to impact both basic research
and clinical outcomes. The identification of previously unknown
genetic alterations (e.g., IDH1/2, NF1, ERBB2, NFKBIA) provides
opportunities for drug development against new therapeutic
targets. Currently, genetic information is becoming more useful
in making a clinical diagnosis and formulating treatment plans.
Though decisions regarding glioma treatment are still mainly
based on traditional pathology relying on histology, molecular
genetic assessment now has an increasing role (Jansen et al.,
2010). One such successful example in glioma is 1p/19q loss,
which frequently occurs in oligodendrogliomas (Jansen et al.,
2010). Patients with high-grade oligodendrogliomas that also
harbor these genetic events have a better prognosis. In low-
grade oligodendrogliomas, 1p/19q loss further dictates favor-
able progression-free survival after temozolomide treatment
(Jansen et al., 2010). It has also been reported that coexpression
of EGFRvIII and the tumor suppressor Pten associates with clin-
ical response to EGFR kinase inhibitor in a recent clinical trial
(Mellinghoff et al., 2005).
The discovery of core signaling pathways in glioma and the
observation that several components of the same pathways
are subject to mutagenesis in tumors also suggested a pathwaytargeting strategy, rather than targeting a single gene, for future
drug discovery efforts (TCGA, 2008; Parsons et al., 2008).
Consistent with this concept, coactivation of several tyrosine
kinases was observed in both xenograft and primary human
GBM specimens. In a cell culture system, targeting these RTKs
concurrently using combinations of inhibitors and/or RNAi
showed significantly better response than treating with a single
agent alone (Stommel et al., 2007).
Continued accumulation of molecular information about
glioma has also led to a reshaping of the classification scheme.
For example, it was initially discovered that lower-grade gliomas
have a higher frequency of TP53 mutation and PDGFRA expres-
sion, thus classifying these two events as markers of secondary
GBM (Ohgaki and Kleihues, 2007). However, TP53 was also
found to be the most frequent somatically mutated gene by the
TCGA project, which predominantly studied primary GBM
samples (TCGA, 2008). Likewise, in the same data set, a subset
of GBMs was also found to overexpress PDGFRA (TCGA, 2008;
Verhaak et al., 2010). These findings, on the one hand, demon-
strate the need to identify additional markers for secondary
GBM. Examples of additional markers are the recently identified
IDH1/2 mutations, which have mainly been found in grade II-III
gliomas (Parsons et al., 2008; Yan et al., 2009). On the other
hand, it is conceivable that primary GBMs actually develop
long before the patient becomes symptomatic. Consistent with
this idea and previous mouse genetic studies (Zhu et al., 2005),
bioinformatic efforts to reconstruct the temporal sequence of
mutations in GBM using the TCGA data set indicated that
the TP53 gene is likely mutated first in the tumorigenic process
(Attolini et al., 2010). It is thus very desirable to develop diag-
nostic techniques to identify those early events for therapeutic
intervention because patients with lower-grade gliomas have
a significantly better prognosis (Ohgaki and Kleihues, 2007).
Genetic Mouse Models of Glioma
The laboratory mouse shares extensive molecular and physio-
logical similarities to humans and is a powerful tool for studying
cancer. Unlike invertebrate model systems, tumor development
in mice is accompanied by other complex processes such as
angiogenesis and metastasis, similar to those in human cancer.
More importantly, mouse tumor models provide temporally and
genetically controlled systems for studying the tumorigenic
process as well as response to treatment. However, initial efforts
to createmousemodels of glioma using single tumor suppressor
knockouts or overexpression of single oncogenes mostly failed
(Reilly and Jacks, 2001). It was subsequently found that, as
confirmed by the TCGA project, the core signaling pathways
are crucial for gliomas: genetically engineered mice that activate
RTK pathways in the brain, along with simultaneous loss of
genes involved in cell-cycle control, develop glioma with high
penetrance. Also, like human gliomas, additional loss of the
tumor suppressor PTEN causes higher-grade malignancy and
reduced survival in mouse glioma models (Kwon et al., 2008).
Catalyzed by the profusion of genetic information arising from
a number of genome-wide studies that revealed mutations
present in human gliomas, as well as advances in molecular
biology tools, dozens of genetic mouse glioma models have
been generated over the last two decades. Though spaceCell 149, March 30, 2012 ª2012 Elsevier Inc. 39
limitations prevent us from describing these various models, we
have summarized them in Table S1 available online.
Genetic mouse models have been widely used to investigate
the cell of origin of malignant glioma (Alcantara Llaguno et al.,
2009; Liu et al., 2011; Uhrbom et al., 2005). Recently, Suzanne
Baker’s group reported the first comprehensive genomic study
of a mouse model of high-grade astrocytoma (HGA) generated
by manipulating tumor suppressors commonly mutated in
human HGAs: Pten, P53, and Rb (Chow et al., 2011). Their
studies revealed an astonishing similarity in gene copy number
and alteration between mouse HGAs and human GBMs. The
mouse tumors also showed similar molecular subtypes as those
found in human malignant gliomas (Chow et al., 2011; Verhaak
et al., 2010). This study demonstrated the physiological rele-
vance and value of mouse glioma models for future preclinical
studies.
As genome-wide sequencing efforts continue in humans, ever
more faithful mouse glioma models that better recapitulate the
complex genomic landscape of human glioma will be generated.
These models will provide increasingly powerful tools for the
validation of hypotheses engendered by human genomic data,
such as confirming the driver mutations that are causal to onco-
genesis, as well as for the preclinical testing of personalized
therapy.
Glioma Stem Cells
Another rapidly progressing yet controversial area in glioma
research is that of cancer stem cells (CSCs). CSCs, as defined
by the American Association for Cancer Research (AACR) work-
shop on CSCs, are a subpopulation of cells in the tumor that
have self-renewal capacity and can give rise to heterogeneous
cancer cells that comprise the tumor (Clarke et al., 2006). Glioma
stem cells (GSCs) were one of the first such type of cells isolated
from solid tumors (Singh et al., 2004). In the original report, as few
as 100 GSCs could give rise to tumors that recapitulated the
parental tumors when implanted in immunodeficient mice,
whereas as many as 1,000,000 non-GSCs could not (Singh
et al., 2004).
Unlike traditional glioma cell culture with serum, GSCs were
cultured in vitro in monolayer or as spheroids using serum-free
medium containing EGF and FGF (Lee et al., 2006; Singh et al.,
2004). Interestingly, GSCs isolated from human tumors and
cultured in vitro showed remarkable similarities to normal neural
stem cells (NSCs), expressing neural stem/progenitor markers
such as Nestin, Sox2, and Olig2 and, upon induction, could be
differentiated to cells expressing neuronal or glial markers. Using
cells derived from the same primary GBM tissues, Lee et al. per-
formed an extensive comparison of traditional serum-containing
culture versus serum-free GSC culture (Lee et al., 2006). They
reported that the genetic content of parental tumors can be
stably preserved under stem cell culture conditions, whereas
cells maintained in serum-containing medium underwent
dramatic genetic and epigenetic changes over time.More impor-
tantly, transplanting GSCs into immunodeficient mice yielded
tumors that shared similar histology and global gene expression
patterns with their parental tumors. By contrast, in serum-con-
taining medium, early passage glioma cells were completely
incapable of tumor formation after transplantation, whereas40 Cell 149, March 30, 2012 ª2012 Elsevier Inc.late-passage glioma cells gave rise to morphologically distinct
tumors containing a different molecular signature than the orig-
inal tumors (Lee et al., 2006). The GSC culture thus provided a
more reliable and physiologically relevant model to study
disease mechanism.
The discovery of GSCs provided a possible explanation for
glioma recurrence following treatment. It was reported that
CD133+ glioma stem cells in vitro were more resistant to radia-
tion compared to the CD133 population due to activation of
DNA repair pathways by CHK1/CHK2 (Bao et al., 2006a). In
addition, GSCs were found to overexpress certain ATP-binding
cassette transporters (ABCTs) such as ABCG2 and to export
the chemotherapy agent temozolomide (TMZ), a mechanism
that was linked to the PTEN/PI3K/AKT pathway (Bleau et al.,
2009). The stem cell properties of GSCs also provide new strat-
egies for therapeutic interventions. Numerous studies have
shown that pathways such as Sonic hedgehog, Notch, and
Wnt, as well as key ‘‘stemness’’ factors such as Olig2, Bmi1,
and Nanog, play important roles in GSC maintenance (Brugge-
man et al., 2007; Ligon et al., 2007; Po et al., 2010; Stiles and
Rowitch, 2008; Zbinden et al., 2010; Zheng et al., 2010). Chem-
ical compounds or RNAi constructs that block components of
those pathways have been shown to slow down GSC growth
in vitro and attenuate tumor formation in transplantation assays.
On the other hand, factors that promote differentiation can be
another viable approach to eliminate CSCs. One such example
is BMP4, which induces astrocytic differentiation of GSCs and
dramatically reduces the tumorigenic potential of CD133+
human GSCs (Piccirillo et al., 2006). Other strategies include
targeting stem cell-specific markers, stem cell niches, and
quiescent stem cells; these strategies have been summarized
in an excellent review article by Zhou et al. (Zhou et al., 2009).
Controversies in the Glioma Stem Cell Field
GSCMarkers. The field of somatic stem cells andCSCs has been
led by the hematopoietic field, in which relatively large subpop-
ulations of cells that grow in suspension can be discerned and
isolated using panels of extracellular epitopes. This permits
effective enrichment and study of specific subpopulations of
stem cells, progenitor cells, or leukemia subtypes (Bonnet and
Dick, 1997). Unfortunately, the solid tumor CSC field has not
benefited as well from such epitope-reliant classifications.
Initially, GSCs were cultured as spheroids in EGF- and
FGF-containing medium, and it was reported that CD133/prom-
inin-1-positive cells were enriched for CSCs (Singh et al., 2004).
However, subsequent studies suggested that CD133 was not
a reliable CSC marker: two different groups reported that
CD133-negative tumor cells isolated from GBMs can be stably
passaged under the same stem cell conditions. Interestingly,
similar to the CD133+ cells, these cells also showed ‘‘stem
cell’’ properties such as self-renewal and differentiation in vitro
and formed transplantable tumors in a xenograft model (Beier
et al., 2007; Joo et al., 2008). One study reported that, unlike
the CD133+ cells, which can form floating spheroids in culture,
the CD133 cells tend to grow as adherent spheres. Recently,
a small population of CD133 cells that can give rise to
CD133+ cells was reported, suggesting a possible stem cell hier-
archy in the spheroid culture system that may or may not have
in vivo relevance (Chen et al., 2010). More generally applicable
Figure 3. The Vascular Niche and Hypoxic Niche of Glioma Stem
Cells
Vascular niches have been found to be important for glioma growth, probably
due to the secreted factors from the endothelial cells within the niche, as well
as the nutrient supply from the blood vessels. On the other hand, constantly
infiltrating glioma stem cells (GSCs) probably maintain their stemness through
activation of hypoxia-related pathways. At the same time, GSCs can recruit
endothelial cells by secreting angiogenic factors or by directly differentiating
into cells of the endothelial lineage, which in turn support glioma growth. EC
and PC are endothelial cell and pericyte cell, respectively.stem cell markers have also been suggested, such as CD44,
CD15, and integrin a 6, although they have not been extensively
validated by the community (Anido et al., 2010; Lathia et al.,
2010; Son et al., 2009).
GSCNiches. It is known that normal NSCs preferentially reside
in specific anatomic regions of the brain: the subventricular zone
(SVZ) and subgranular layer (SGZ) (Zhao et al., 2008). In those
regions, specific cells, including endothelial and ependymal
cells, form a niche that nourishes the NSCs and supports their
self-renewal (Shen et al., 2004). This ‘‘seed-and-soil’’ relation-
ship has been adapted in CSC research, as CSCs also require
a specificmicroenvironment tomaintain their ‘‘stem cell’’ proper-
ties. Like normal NSCs, Nestin+ and CD133+ GSCs have been
reported to reside in a vascular niche (Calabrese et al., 2007).
Coculturing CD133+ GSCs with endothelial cells enhanced
their proliferation in vitro. Coimplantation of both CD133+ and
endothelial cells promoted tumor growth in a xenograft model,
whereas angiogenesis antagonists eradicated GSCs and signif-
icantly slowed tumor growth (Calabrese et al., 2007). However,
the in vitro observation from coculture experiments could poten-
tially be compromised by the strong mitogenic effect of growth
factors in the cell culture medium, and the putative ‘‘stem cell’’
markers Nestin and CD133 are also expressed by endothelial
cells, making the immunohistochemistry results unreliable (Kelly
et al., 2007; Klein et al., 2003). Furthermore, a ‘‘chicken or egg
first’’ paradox exists in the vascular niche hypothesis, as GSCs
themselves can elicit angiogenic effects by secreting factors
such as SDF-1 and VEGFA (Bao et al., 2006b; Folkins et al.,
2009). Under certain conditions, GSCs can even directly trans-differentiate into the endothelial lineage, making it difficult to
determine whether the vascular niche is required for glioma
stem cell maintenance (Ricci-Vitiani et al., 2010; Wang et al.,
2010). Finally, the vascular niche hypothesis fails to explain
several clinical and experimental observations. Malignant glioma
cells are notoriously infiltrative and invariably recur after surgical
removal of the tumor, suggesting that the peripheral regions of
the tumor contain residual tumor cells. Histological observations
from both human GBM samples and mouse tumor models
suggest that glioma cells typically migrate along white matter
(WM) tracts and not their proposed vascular niches (Louis
et al., 2007). It is known that hypoxic conditions facilitate self-
renewal of both NSCs and GSCs in culture (Clarke and van der
Kooy, 2009; Li et al., 2009c). HIF-2a was reported to regulate
tumorigenic potential of GSCs, and its expression correlates
with poor clinical outcome of glioma patients (Li et al., 2009c).
A high percentage of CD133-positive cells was also observed
in the pseudopalisade formations that delineate the necrotic
center of GBMs, which was thought to be caused by hypoxia
(Christensen et al., 2008). In vivo, deletion of HIF-1a resulted
in a decline in hippocampal neurogenesis (Mazumdar et al.,
2010). It is thus difficult to reconcile the function of hypoxia in
neural/glioma stem cells with the vascular niche hypothesis,
wherein high levels of oxygen are supplied to neighboring stem
cells. Additionally, in several mouse tumor models, inhibition of
angiogenesis can shrink the original tumor but also promotes
malignant progression by increasing tumor cell invasion and
metastasis (Ebos et al., 2009; Pa`ez-Ribes et al., 2009). Similar
findings have been observed in bevacizumab-treated GBM
patients inwhom the tumor phenotype shifted to a predominantly
infiltrative pattern (de Groot et al., 2010; di Tomaso et al., 2011).
As a result, bevacizumab treatment leads to prolonged progres-
sion-free survival, but not overall survival time (T.F. Cloughesy
et al., 2008, ASCO, abstract). Therefore, there could be more
than one defined niche for GSCs (Figure 3). A hypoxic environ-
ment could be one such niche. Hypoxia promotes GSC (most
likely quiescent because of a lack of nutrient supply) infiltration.
The infiltrating GSCs, under certain conditions, can home to
vascular niches or recruit endothelial cells by secretion of
chemokines such as SDF-1. Similar to what has been observed
for normal NSCs (Kokovay et al., 2010), the newly established
nutritional source then activates the quiescent cancer cells to
proliferate and colonize new tumors.
CSC Assays. CSCs were defined as cells that maintain the
tumor in vivo (Clarke et al., 2006). Paradoxically, the field relies
entirely on the assessment and study of CSCs by prospective
isolation of a subpopulation of cells from tumors and ex vivo
culture or tumorigenic assays using immunodeficient rodents
(Clarke et al., 2006). Thus, the behavior of the transplanted
cancer cells outside of their original environment is studied,
and the readout is inferred to reflect how the cells would behave
in their original tumor environment. Although the tumorigenic
assay of serially transplanting cells into immunodeficient hosts
is considered a validation of CSCs, the ability to form a tumor
in an immunodeficient host does not necessarily correlate with
the implicit definition of a CSC, which is concerned with its
presumed role in tumor development and maintenance in vivo
(Jordan, 2009; Quintana et al., 2008). In fact, primary gliomaCell 149, March 30, 2012 ª2012 Elsevier Inc. 41
Figure 4. Cancer Maintenance Models
(A) Clonal evolution model. In this model, tumor cells are equivalent, and a majority of the tumor cells have the ability to sustain tumor growth.
(B) Traditional view of the cancer stem cell model. In this model, a stable hierarchy exists in the cells of the tumor, whereby only cancer stem cells have the ability
to self-renew and contribute to long-term maintenance of tumor growth.
(C) Evolutional view of cancer stem cell model. This model posits that the hierarchical structure of cancer stem cells is constantly evolving due to natural selection
and genomic instability. New cancer stem cell clones with different genetic alterations emerge over time. Certain genetic events will ultimately confer most tumor
cells with self-renewal capacity without the reliance of niches or stemness factors (dashed arrows).cells, as well as traditionally established glioma cell lines, in
serum-containing ‘‘non-stem cell’’ culture condition, can form
tumors when transplanted. Whereas primary gliomas can be
classified into PN, MES, and proliferative subtypes (Phillips
et al., 2006), xenograft tumors from glioma cell lines all express
high levels of proliferative markers (Hodgson et al., 2009).
Recently, it has also been reported that the variability of the
transplantation assay could greatly impact the estimation of
CSC frequency (Boiko et al., 2010; Quintana et al., 2008). New
technologies or model systems are needed to permit direct
evaluation of putative GSCs in native tumor development and
maintenance.
Finally, CSC nomenclature was adopted from normal tissue
stem cells to describe the abilities required for maintaining tumor
growth: self-renewal and giving rise to other tumor cells. The
CSC concept and properties are frequently confused with the
concept and properties of normal tissue stem cells (Jordan,
2009). The hierarchy of normal tissue stem cells is well defined
and conserved. In contrast, tumors show a huge degree of
diversity. For example, CSCs in mouse models of lung cancer
driven by different mutations express distinct surface antigens
(Curtis et al., 2010).
Possible Causes Underlying These Controversies. The incon-
sistent findings observed in GSC research could be due to the
fact that gliomas can be classified into several subtypes accord-
ing to either pathology or molecular genetics. In fact, it was re-
ported that GSC spheroids could not be derived from secondary
GBMs (Beier et al., 2007). CD133- GBMs usually show different
histology, and the GSCs isolated from these tumors harbor
distinct molecular signatures compared to CD133+ tumors (Be-
ier et al., 2007; Joo et al., 2008). Additionally, although spheroid
cultures can be established from various brain tumor types in
addition to glioma, these cultures can display distinct properties.
For example, addition of BMP4 to GSCs isolated from astrocytic
tumors and GBM can efficiently differentiate these cells,
whereas it has only a minor effect on spheroids isolated from
oligodendrogliomas (Persson et al., 2010; Piccirillo et al.,42 Cell 149, March 30, 2012 ª2012 Elsevier Inc.2006). Likewise, even in the same tumor, CSCs are not likely to
be a static population: multiple clones of CSCs with diverse
genetic alterations could exist, and those stem cells would be
under selective pressure at the same time (Figure 4).
It has been suggested that the tumor ismaintained by a cellular
hierarchy that is similar to Darwin’s evolutionary tree structure
rather than a linear hierarchical structure (Greaves, 2010).
Consistent with this idea, Piccirillo et al. isolated two ‘‘stem-
like’’ cell populations from the periphery and the core of the
same GBM samples that display distinct tumorigenic potential
and cytogenetic profiles (Piccirillo et al., 2009). The heteroge-
neity of tumor phenotypes is thus likely to be determined by
both the clonal diversity of CSCs and their differentiation
capacity. Another theory, yet to be demonstrated in vivo, posits
that the progeny of CSCs are plastic and can revert back to a
stem cell-like state. In melanoma, it was reported that a slow-
cycling JARID1B-positive population that can give rise to
JARID1B-negative cells is essential for tumor growth and for
preventing growth exhaustion (Roesch et al., 2010). However,
in contrast to the typical unidirectional hierarchy of cancer
stem cells, the JARID1B-expressing population is not predeter-
mined and can be dynamically changed. Using cell line models,
Weinberg et al. proposed another hypothesis: that a process
similar to epithelial to mesenchymal transition (EMT) could lead
to conversion of the non-CSCs and CSC compartments (Mani
et al., 2008). EMT is a developmentally regulated process and
is believed tomediate breast cancermetastasis; breast epithelial
cells that have undergone EMT showed CSC characteristics
(Mani et al., 2008). It is known that sphere-forming cells in
wild-type SVZ neural stem cell culture are mostly derived from
the progenitor cells that respond to EGF and FGF stimulation
(Doetsch et al., 2002). Whether similar processes are also
involved in glioma development in vivo is still unclear.
Cell of Origin of Glioma
We have discussed the notion that differences in genetic alter-
ations could be responsible for generating glioma subtype
diversity. Another potential contributing factor to heterogeneity
Figure 5. Cell of Origin of Gliomas
Mutations in adult neural stem cells are sufficient
to drive malignant glioma formation in vivo. Some
evidence for progenitors or mature astrocytes as
the cells of origin has been demonstrated in vitro
and in vivo. However, strict proof has not yet been
shown due to the lack of specific in vivo lineage
markers.could be the tumor cell of origin. Cells of origin are the normal
cells in which tumorigenic mutations first occur and accumulate
to form a full-blown malignancy. CSCs, on the other hand, are
defined as the cells that maintain an already formed tumor.
Unfortunately, the two concepts are frequently confused, espe-
cially when CSCs are also referred to as ‘‘tumor-initiating cells.’’
As Jane E. Visvader pointed out, the term ‘‘tumor-initiating cells’’
is more in line with the ‘‘cells of origin,’’ whereas CSCs would
more accurately be referred to as ‘‘tumor-propagating cells’’
(Visvader, 2011).
Prior to the discovery of adult NSCs, astrocytes were thought
to be the origin of gliomas, as they were the only known replica-
tion-competent population (Figure 5). The malignant transforma-
tion process in this scenario requires a ‘‘dedifferentiation’’
process by which differentiated cells regain immature glial and
progenitor properties. The feasibility of this dedifferentiation
process is supported by recent findings demonstrating that a
certain transcription factor cocktail can reprogram terminally
differentiated cells back to pluripotent embryonic stem cells
(Takahashi and Yamanaka, 2006). Indeed, neonatal cortical
astrocytes in culture can be reverted back to a neural stem/
progenitor-like status by deleting the tumor suppressors
INK4a/ARF or prolonging treatment with growth factors (Bachoo
et al., 2002). Several studies reported successful generation of
gliomas by transforming early cortical astrocytes in vitro and
in vivo (Bachoo et al., 2002; Uhrbom et al., 2005). However,
evidence supportingmature astrocytes as possible cells of origin
of gliomas is still lacking. In vivo efforts using genetically engi-
neered mice or viral delivery were limited by the lack of a good
mature astrocyte marker. It is now well known that the widely
used ‘‘astrocyte’’ marker GFAP is also expressed by adult
NSCs (Figure 5) (Doetsch et al., 1999). In vitro, culturing mature
astrocytes is extremely difficult, and astrocyte cultures from
neonatal mouse cortex were reported to contain immature pro-
genitor cells (Laywell et al., 2000). In addition, transformation of
neonatal astrocytes relies on deletion of INK4a/ARF in many
studies. Given their roles in reprogramming and aging (Li et al.,Cell 12009b; Utikal et al., 2009), whether the
germline deletion of INK4a/ARF itself
affects glial maturation is still unclear
and thus further compromises the inter-
pretation of these studies.
The rediscovery of self-renewing NSCs
in postnatal mammalian brains (Zhao
et al., 2008) provided an attractive alter-
native candidate for the glioma cell of
origin (Figure 5). Self-renewal capacity
gives the NSCs a natural ‘‘advantage’’ inaccumulating oncogenic mutations. The oncogenic process
can then be viewed as NSCs losing control over their self-
renewal and differentiation properties. Several lines of evidence
suggest that NSCs are more susceptible to malignant transfor-
mation. (1) Abnormalities first occur in the NSC niches of
pretumorigenic mice in spontaneous mouse models of glioma
(Kwon et al., 2008; Zhu et al., 2005). (2) Temporally deleting the
tumor suppressors P53, NF1, and Pten specifically in postnatal
mouse neural stem/progenitor cells using a tamoxifen-inducible
Nestin-Cre resulted in glioma formation with 100% penetrance,
whereas ablation of these genes in nonneurogenic adult brain
regions using Cre adenovirus did not produce tumors (Alcantara
Llaguno et al., 2009). Similarly, ablation of P53, Pten, and/or Rb
in SVZ stem cells, but not in peripheral astrocytes, yielded
gliomas (Jacques et al., 2010). It should be noted that these
experiments were unable to distinguish between the more
quiescent, long-term self-renewing NSCs and the more rapidly
dividing progenitor cells, which have limited self-renewal poten-
tial. Recently, Liu et al. used mosaic analysis with double
markers (MADM) to elegantly demonstrate that the early expand-
ing tumor cell populations in the Nf1;P53-based mouse oligoas-
trocytoma model are cells that express OPC markers (Liu et al.,
2011). In addition, gliomas can be formed by deletion of NF1 and
P53 in NG2+ cells, the majority of which are OPCs (Liu et al.,
2011). Nevertheless, similar caveats also exist in those studies.
Human glioma cells are known tomigrate through theWM tracts,
and the oligodendrocyte lineage marker PDGFRA is expressed
by both NSCs and OPCs (Figure 5) (Jackson et al., 2006). In vivo,
NG2 is expressed by multiple cell types, including OPCs, peri-
cytes, and microglial cells (Richardson et al., 2011). A population
of multipotent NG2+ cells was also identified in the mouse brain
(Aguirre et al., 2004; Rivers et al., 2008; Zhu et al., 2008); it is still
unknown whether those cells have long-term self-renewal
capacity. Interestingly, lineage tracing of NG2+ cells revealed
that they can give rise to both oligodendrocytes and gray matter
astrocytes (Zhu et al., 2008). Similarly, a bipotent NG2-positive
oligodendrocyte type 2 astrocyte progenitor cell population49, March 30, 2012 ª2012 Elsevier Inc. 43
can be isolated and differentiated to either OPCs or type 2 astro-
cytes, depending on the medium in vitro. However, the in vivo
counterpart of such type 2 astrocytes is still a mystery (Richard-
son et al., 2011). Finally, SVZ NSCs can differentiate into oligo-
dendrocytes and migrate into the WM (Menn et al., 2006). This
process can be greatly enhanced by EGF infusion (Gonzalez-
Perez and Alvarez-Buylla, 2011), and amplification of EGFR
was frequently identified in both astrocytomas and oligodendro-
gliomas (Persson et al., 2010).
Mouse models are important tools for investigating and vali-
dating the cell of origin and the natural history of cancers, and
it is critical that genetic alterations and physiological setting of
tumor development closely resemble that seen in human
patients. In addition, cell-of-origin studies address tumor devel-
opment and progression, which usually takes years if not
decades in human patients. An ideal model system for studying
the cell of origin should not only address whether the cells are
capable of transformation following a set of simultaneous onco-
genic events, but also by accumulation of mutations over time.
Knowledge of cell-specific markers combined with technologies
that achieve more precise temporal and spatial somatic gene
manipulation would greatly facilitate future studies. Histopa-
thology and higher-resolution molecular genetic analyses (e.g.,
single-cell analysis) of patient samples at different stages will
also provide valuable information. For example, Lai et al. care-
fully examined human GBMs containing the IDH1 R132 mutation
and observed a number of unique features that distinguished
them from other GBMs, including predominantly frontal lobe
involvement (Lai et al., 2011). Their conclusion from these pheno-
typic differences was that the IDH R132 GBMs most likely arise
from unique cell types of origin. Microarray studies of human
GBM samples revealed that different molecular subtypes share
similarity with profiles of different neural lineages, suggesting
potentially different origins (Verhaak et al., 2010). However,
studies in other solid tumors, including breast cancer, pancreatic
tumors, and basal cell carcinomas, reported that histopathology
and molecular markers of malignant tumors can be misleading.
Breast cancers with BRCA1 mutations usually show basal cell-
like marker expression even though they arise from luminal
progenitor cells (Lim et al., 2009). Also, early abnormalities
were observed in the acinar cells from Kras-driven pancreatic
duct carcinomas (De La O et al., 2008). It has yet to be deter-
mined whether a similar phenomenon occurs in the origin of
gliomas.
Conclusions
Although many questions and controversies remain, our under-
standing of malignant glioma has increased dramatically in
recent years. For the first time, we have a clear picture of the
human GBM genomic landscape. The continued incorporation
and validation of new data using ever more sophisticated animal
models will further advance our knowledge of disease origin,
progression, and treatment. At the same time, despite the prob-
lems outlined, the CSC theory not only points to new cancer tar-
geting strategies from aspects of developmental biology, but
also provides insights into tumor maintenance, therapy resis-
tance, and recurrence. The accumulation of this knowledge
provides great opportunities to improve and even revolutionize44 Cell 149, March 30, 2012 ª2012 Elsevier Inc.current diagnosis and treatment of human malignant glioma,
especially GBM, which typically causes mortality within 1 year.SUPPLEMENTAL INFORMATION
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